skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most common cancers worldwide and the 5 years survival rate of the patients is about 60% in the USA, due to acquired chemotherapeutic resistance and metastasis of the disease. In this study, we found that tivantinib, a selective MET inhibitor, suppresses OCSS cell proliferation and colony formation, however, anti-tumor activities induced by tivantinib are independent of the inhibition of MET signaling pathway. In addition, tivantinib cause G2/M cell cycle arrest and caspases-dependent apoptosis in OSCC cell lines. We also found that tivantinib dose-dependently suppressed the activation and expression of FAK. In all, these data suggested that tivantinib may be developed as a chemotherapeutic agent to effectively treat certain cancers including OSCC. - Highlights: • Tivantinib suppresses OSCC cell growth independent of the inhibition of HGF/MET signaling pathway. • Tivantinib blocks cell cycle and induces caspases-mediated apoptosis. • Tivantinib elicits its anti-tumor activity with the inhibition of FAK signaling pathway.

Authors:
 [1];  [2];  [1];  [1]
  1. Department of Oral and Maxillofacial Surgery, First Affiliated Hospital, Nanchang University, Nanchang 330006 (China)
  2. Department of Blood Transfusion, First Affiliated Hospital, Nanchang University, Nanchang 330006 (China)
Publication Date:
OSTI Identifier:
22458496
Resource Type:
Journal Article
Resource Relation:
Journal Name: Biochemical and Biophysical Research Communications; Journal Volume: 457; Journal Issue: 4; Other Information: Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; APOPTOSIS; CARCINOMAS; CELL CYCLE; CELL PROLIFERATION; COLONY FORMATION; DOSES; INHIBITION; METASTASES; PATIENTS; PLANT GROWTH; SIGNALS

Citation Formats

Xi, Wei-Hong, Yang, Li-Yun, Cao, Zhong-Yi, E-mail: m18070383032@163.com, and Qian, Yong, E-mail: yfykqkqy@163.com. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma. United States: N. p., 2015. Web. doi:10.1016/J.BBRC.2015.01.062.
Xi, Wei-Hong, Yang, Li-Yun, Cao, Zhong-Yi, E-mail: m18070383032@163.com, & Qian, Yong, E-mail: yfykqkqy@163.com. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma. United States. doi:10.1016/J.BBRC.2015.01.062.
Xi, Wei-Hong, Yang, Li-Yun, Cao, Zhong-Yi, E-mail: m18070383032@163.com, and Qian, Yong, E-mail: yfykqkqy@163.com. Fri . "Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma". United States. doi:10.1016/J.BBRC.2015.01.062.
@article{osti_22458496,
title = {Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma},
author = {Xi, Wei-Hong and Yang, Li-Yun and Cao, Zhong-Yi, E-mail: m18070383032@163.com and Qian, Yong, E-mail: yfykqkqy@163.com},
abstractNote = {Oral squamous cell carcinoma (OSCC) is one of the most common cancers worldwide and the 5 years survival rate of the patients is about 60% in the USA, due to acquired chemotherapeutic resistance and metastasis of the disease. In this study, we found that tivantinib, a selective MET inhibitor, suppresses OCSS cell proliferation and colony formation, however, anti-tumor activities induced by tivantinib are independent of the inhibition of MET signaling pathway. In addition, tivantinib cause G2/M cell cycle arrest and caspases-dependent apoptosis in OSCC cell lines. We also found that tivantinib dose-dependently suppressed the activation and expression of FAK. In all, these data suggested that tivantinib may be developed as a chemotherapeutic agent to effectively treat certain cancers including OSCC. - Highlights: • Tivantinib suppresses OSCC cell growth independent of the inhibition of HGF/MET signaling pathway. • Tivantinib blocks cell cycle and induces caspases-mediated apoptosis. • Tivantinib elicits its anti-tumor activity with the inhibition of FAK signaling pathway.},
doi = {10.1016/J.BBRC.2015.01.062},
journal = {Biochemical and Biophysical Research Communications},
number = 4,
volume = 457,
place = {United States},
year = {Fri Feb 20 00:00:00 EST 2015},
month = {Fri Feb 20 00:00:00 EST 2015}
}